Serum Institute of India (SII) on Wednesday said that drugmaker will follow the central drug regulator's instruction on suspension of the Oxford-AstraZeneca COVID-19 vaccine trial in India.The Drugs Controller General of India (DCGIon Wednesday issued a show-cause notice to Serum Institute of India for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine candidate for COVID-19 in other countries.On September 8, the clinical trials of one of the Oxford-AstraZeneca's COVID-19 vaccine were suspended in the United Kingdom after a participant developed an unexplained illness.In his show-cause notice, Dr V G Somani asked SII as to why the permission granted for conducting phase 2 and 3 clinical trials.
Read more on livemint.com